Navigation Links
d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014

(PRWEB) January 11, 2013

U.S. District Court in the Eastern District of Pennsylvania Judge Cynthia M. Rufe announced during a Pre-trial order issued last month that the first Zoloft birth defects trial is set for September 14, 2014. See In re: Zoloft (Sertraline Hydrochloride) Prods. Liab. Litig., 856 F. Supp. 2d 1347 (J.P.M.L. 2012). There have been approximately 250 Zoloft birth defects pending in the MDL. Even in this past August, as many as 5 lawsuits were added to the MDL in one day. The announcement indicated that so long as all the appropriate discover had been completed at that time, the trial would begin. The judge also mentioned that the first trial would not begin until at least eight months after the briefing of any challenges to expert testimony that may be offered. Additionally, the bellwether trials are set to undergo discovery specific to the cases by January 11, 2013. The bellwether trials are cases that are chosen from the pool of cases in the MDL to do trial case runs in front of a jury so that the judge can have a better idea of how the MDL will go as MDLs are expensive and they want to avoid wasting resources.

As recent as November 19, 2012, the Zoloft MDL in Pennsylvania added a new lawsuit filed by a mother whose child was born with autism as well as other life-threatening physical birth defects after she used Zoloft while pregnant. This lawsuit alleges that although Pfizer knew about the defects as far back as the 1990s, the company continued to market their drugs without the appropriate warnings. This baby was born with multiple birth defects including anemia of prematurity, which is characterized by low red blood cell count and often requires transfusions; tracheoesophageal fistula, an abnormal connection between the trachea and esophagus, which requires surgery soon after birth; and double outlet right ventricle, a heart defect that often requires surgery.

The other Zoloft birth defect lawsuits claim that Pfizer knew or should have known that the drug has the potential to cause the birth defects, but that it failed to warn both the public and the medical communities about the risk. Pfizer has also been accused of encouraging the doctors to prescribe Zoloft to women of childbearing age and considers pregnant women one of their primary marketing targets while knowing the dangerous defects the drug could cause. In 2007, Zoloft succeeded in becoming the most widely prescribed antidepressant in the U.S. with nearly 30 million prescriptions filled annually despite the seriousness of its side effects, putting millions of women and unborn children at risk.

The attorneys at d'Oliveira & Associates urge anyone who has taken Zoloft and have suffered any serious birth defects or know someone who has suffered birth defects due to Zoloft to contact them and find out if you are entitled to compensation. They are working with some of the leading dangerous drugs attorneys in the nation who are handling these cases. They want all patients who have used Zoloft to understand that they are entitled to compensation.

For a free legal consultation, call 1-800-992-6878 or visit their website at Zoloft Lawyer

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
2. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
3. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
4. d'Oliveira & Associates Helps Rhode Island Estate Receive the Maximum Compensation Under RI Law of $250,000 Settlement for Fatal Auto Accident
5. d'Oliveira & Associates Helps Westport, MA Man Receive $100,000 Settlement for Reckless Driving Accident
6. d'Oliveira & Associates Help New Bedford Woman Receive $95,000 in Damages for Dog Bite Injury Case #:NB-11736
7. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
8. Steinger, Iscoe & Greene Offers Tips With New Recommendations
9. ILVO-T&V Belgium Validates Charm Sciences ROSA Beta-Lactam and Tetracycline 2-Minute Test for Raw, Commingled, Bovine Milk to be Imported by Customs Union Countries
10. Philadelphia Malpractice Lawyers at Console & Hollawell Explore Negligence as Overdoses from Prescription Painkillers Now Kill More People than Heroin
11. Dr. Kent Stobaugh Retiring from Oral & Maxillofacial Surgeons to Pursue Different Opportunities: SA4i Emphasizes Significant Contributions to People’s Lives
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: